Tadalafil Tablets 20 mg recalled due to manufacturing deviations
Northwind Pharmaceuticals voluntarily recalls Tadalafil 20 mg tablets nationwide due to manufacturing practice deviations. No illnesses have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a voluntary, precautionary FDA Class II recall with no reported illnesses or injuries. The specific manufacturing deviations are not detailed in the source, leaving the actual product hazard theoretical rather than established.
Plain-English summary
Northwind Pharmaceuticals LLC is voluntarily recalling Tadalafil Tablets, USP 20 mg distributed nationwide in the United States. The recall affects two package sizes: 6-count bottles (NDC 51655-473-87) and 15-count bottles (NDC 51655-473-54). Specific lot numbers and expiration dates are available in FDA recall notice D-0553-2023.
The recall was initiated due to deviations from Current Good Manufacturing Practice (CGMP) standards. No illnesses or injuries have been reported. This is a voluntary FDA Class II recall initiated by the manufacturer on March 16, 2023.
Patients currently taking Tadalafil should verify the lot and expiration date of their medication against those listed in the recall notice. Those with affected batches should consult their healthcare provider before taking any action. Healthcare providers and pharmacists should be alert to patients inquiring about this recall.
The recalled product
- Product
- TADALAFIL (TADALAFIL)
- Brand
- TADALAFIL
- Manufacturer
- Northwind Pharmaceuticals LLC
- Category
- Drug — Prescription
- Hazard
- manufacturing-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (8)
- a) Lot #: F113892002
- Exp. Date 08/31/2023
- F113892201
- Exp. Date 11/30/2023 b) Lot #: F113892001
- F113892202
- Exp. Date 11/30/2023
- F113892203
- Exp. Date 12/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · TADALAFIL
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-05-03
- ModeratePrescription Tadalafil tablets recalled for manufacturing process deviations
FDA (Drugs) · 2023-04-12
- ModerateTadalafil tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil tablets recalled for manufacturing quality control deviations
FDA (Drugs) · 2023-03-08
- HighTadalafil Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27